Axsome Therapeutics Raises Auvelity Peak Revenue Forecast After FDA Approval to At Least 8 Billion USD!
Reading Time: 3 minutes
The FDA approval for Auvelity to treat agitation in Alzheimer’s dementia opens up a new billion-dollar market. The peak revenue potential has been raised to at least 8 billion USD. Revenue jumped 57% in the first quarter, primarily driven by the resounding success of the antidepressant Auvelity. With massive investments in sales and marketing campaigns, further expansion is initially prioritized at the expense of profitability. The stock marks a new all-time high. Axsome Therapeutics (AXSM) focuses as an emerging biopharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
